MTHFD2 Inhibitor

About Iktos

Iktos is a pioneering AI-native drug discovery company building an integrated, automated platform to radically shorten the early-stage R&D timeline. Its core technology combines the generative AI software Makya for molecular design, the retrosynthesis AI Spaya for synthesis planning, and proprietary robotics systems for automated chemical synthesis and biological testing. This closed-loop Design-Make-Test-Analyze (DMTA) cycle enables rapid iteration and optimization of drug candidates. The company validates its platform through both external collaborations with major pharma partners and an internal pipeline of proprietary programs targeting challenging biological mechanisms.

Therapeutic Areas